ASCO GU 2021: Clinical Outcomes of Patients With mCRPC Receiving Radium-223 Early Versus Late in the Treatment Sequence
SHARE ASCO GU 2021: Clinical Outcomes of Patients With mCRPC Receiving Radium-223 Early Versus Late in the Treatment Sequence Published 11 February 2021 (UroToday.com) Data from the landmark ALSYMPCA trial 1 found that the targeted alpha therapy Radium-223 prolonged overall survival in men with metastatic castration-resistant prostate cancer (mCRPC). 1 However, there is little data to guide clinicians as to the appropriate sequence for use of Radium-223 in men with mCRPC with regards to other life-prolonging therapies. At the 2021 ASCO Genitourinary Cancers Symposium (ASCO GU), Dr. Lawren...